ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has raised an undisclosed amount of funding from Guangzhou LBP Medicine Science & Technology Co., Ltd. The collaboration will focus on advancing digital polymerase chain reaction (PCR) technology, including product research and development (R&D), manufacturing, and marketing.
Company Overview and Technology
ThunderBio, incubated at the Hong Kong University of Science and Technology in 2018, has R&D centers in Shenzhen, Jiaxing, and Hong Kong, as well as a production base integrating the production of microfluidic chips, instruments, and reagents. The company’s core technology, droplet microfluidics, can quickly divide the reaction system into micron-level microdroplets, with each microdroplet conducting independent reactions. Basic operations of biochemical experiments, such as sample reaction, preparation, separation, and detection, are integrated into the chip, significantly improving reaction throughput and sensitivity. This technology has enabled ThunderBio to develop platforms for digital PCR, single-cell sequencing, and high-throughput screening.
Future Outlook
The partnership with Guangzhou LBP Medicine Science & Technology Co., Ltd marks a significant step for ThunderBio in expanding its capabilities in the digital PCR field. By leveraging the strengths of both companies, the collaboration aims to drive innovation and enhance the availability of advanced molecular diagnostic solutions.-Fineline Info & Tech
